Compare TCRT & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | ACON |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.7M |
| IPO Year | 2025 | N/A |
| Metric | TCRT | ACON |
|---|---|---|
| Price | $2.15 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 17.1K | ★ 78.4K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,900,000.00 | N/A |
| Revenue This Year | N/A | $87.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $2.34 |
| 52 Week High | $5.48 | $12.03 |
| Indicator | TCRT | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 37.20 |
| Support Level | $1.92 | $2.38 |
| Resistance Level | $2.37 | $3.55 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 25.49 | 11.35 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.